分析雷贝拉唑配合莫沙必利在胃食管反流所致慢性喉炎治疗的效果

To analyze the effect of rabeprazole combined with mosapride in the treatment of chronic laryngitis caused by gastroesophageal reflux

目的评估雷贝拉唑+莫沙必利应用在胃食管反流病(GERD)所致慢性喉炎(CL)治疗中的效果。方法纳入2019年1月一2022年7月的76例GERD所致CL患者,参照随机数字表法划分对照组(纳入38例,采用雷贝拉唑)、观察组(纳入38例,行雷贝拉唑+莫沙必利治疗),评价组间治疗有效率、实验室指标、反流体征评分(RFS)、反流症状指数(RSI)、36项健康调查简表(SF-36)、不良反应。结果(1)较之对照组(81.58%),观察组治疗有效率(97.37%)更高,P<0.05;(2)治疗8周后,观察组实验室指标、RFS、RSI、SF-36更佳,P<0.05;(3)在不良反应方面,观察组(7.89%)与对照组(10.53%)无差异,P>0.05。结论对GERD所致CL患者行雷贝拉唑+莫沙必利治疗,疗效显著,不良反应少,可以尽快缓解症状,改善实验室指标,提高生活质量,值得推广。

Objective To evaluate the efficacy of Rabeprazole+Mosapride in the treatment of chronic laryngitis(CL)caused by gastroesophageal reflux disease(GERD).Method A total of 76 patients with Gerd-induced CL from January 2019 to July 2022 were included and divided into control group(38 patients included,receiving rabeprazole)and observation group(38 patients included,receiving rabeprazole+Moxapride)according to random number table method.Intergroup response rate,laboratory indicators,reflux sign score(RFS),reflux symptom index(RSI),36 health survey summary form(SF-36),and adverse reactions were evaluated.Results(1)Compared with the control group(81.58%),the effective rate of the observation group(97.37%)was higher,P<0.05;(2)After 8 weeks of treatment,the laboratory indexes,RFS,RSI and SF-36 in the observation group were better,P<0.05;(3)There was no difference in adverse reactions between the observation group(7.89%)and the control group(10.53%),P>0.05.Conclusion Rabeprazole+Moxapride therapy for GerD-induced CL patients has significant efficacy,less adverse reactions,can relieve symptoms as soon as possible,improve laboratory indicators,and improve quality of life,which is worthy of promotion.